Novel protein markers of androgen activity in humans: proteomic study of plasma from young chemically castrated men

Background:& nbsp;Reliable biomarkers of androgen activity in humans are lacking. The aim of this study was, therefore, to identify new protein markers of biological androgen activity and test their predictive value in relation to low vs normal testosterone values and some androgen deficiency linked pathologies.& nbsp;Methods:& nbsp;Blood samples from 30 healthy GnRH antagonist treated males were collected at three time points: (1) before GnRH antagonist administration; (2) 3 weeks later, just before testosterone undecanoate injection, and (3) after additional 2 weeks. Subsequently, they were analyzed by mass spectrometry to identify potential protein biomarkers of testosterone activity. Levels of proteins most significantly associated with testosterone fluctuations were further tested in a cohort of 75 hypo- and eugonadal males suffering from infertility. Associations between levels of those markers and cardiometabolic parameters, bone mineral density as well as androgen receptor (AR) CAG repeat lengths, were explored.& nbsp;Results:& nbsp;Using receiver operating characteristic analysis, 4-hydroxyphenylpyruvate dioxygenase (4HPPD), insulin-like growth factor-binding protein 6 (IGFBP6), and fructose-bisphosphate aldolase (ALDOB), as well as a Multi Marker Algorithm, based on levels of 4HPPD and IGFBP6, were shown to be best predictors of low (< 8 nmol/l) vs normal (> 12 nmol/l) testosterone. They were also more strongly associated with metabolic syndrome and diabetes than testosterone levels. Levels of ALDOB and 4HPPD also showed association with AR CAG repeat lengths.& nbsp;Conclusions:& nbsp;We identified potential new protein biomarkers of testosterone action. Further investigations to elucidate their clinical potential are warranted.

Automated summary

This study aimed to identify new protein biomarkers of testosterone activity and assess their predictive value in relation to testosterone levels and androgen deficiency-related pathologies. Through mass spectrometry analysis, 4-hydroxyphenylpyruvate dioxygenase (4HPPD), insulin-like growth factor-binding protein 6 (IGFBP6), and fructose-bisphosphate aldolase (ALDOB), as well as a Multi Marker Algorithm based on levels of 4HPPD and IGFBP6, were identified as the most accurate predictors of low testosterone levels. They were also found to be more strongly associated with metabolic syndrome and diabetes compared to testosterone levels. Further investigations are needed to determine the clinical potential of these biomarkers.